Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH
The article reviews post-earnings outlooks for four “Dividend Kings”: Becton Dickinson (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH). It cites quarterly results, cash flow, and updated FY26 guidance. BDX reported Q3 adjusted EPS $3.23 vs $3.14, ED Q2 EPS 83c vs 74c, EMR Q3 EPS $1.71 vs $1.68, and PH FY4 EPS $9.27 vs $8.29.
How this was made
The 30-second read
Why it matters
Traders can use the disclosed EPS beats, guidance range updates, and order/backlog and cash-flow metrics to gauge near-term estimate revision risk and relative momentum across the four names.
Market read
Among the four, EMR has the clearest combination of beat plus raised guidance and improving orders/margins, while ED is framed as stable but not a strong near-term setup.
What to watch
For BDX, the text notes margin pressure and portfolio transformation; for ED, purchased-power and fuel cost pressure could re-emerge; for PH, the excerpt truncates details that could matter for forward margin/cash-flow expectations.
Background
The piece is a multi-stock “Dividend Kings after earnings” roundup, using each company’s latest quarterly results and updated guidance to frame buy/sell/hold views.
Ticker impact
BDX reported fiscal Q3 adjusted EPS of $3.23 vs $3.14 and tightened FY26 adjusted EPS outlook to $12.62-$12.72.
Near-term upside bias, but likely capped by the article’s “Hold” framing and valuation not described as stretched.
The text provides concrete EPS/revenue beats and an updated guidance range, which are actionable for estimate revisions, but it does not indicate a major re-rating catalyst beyond the modest outlook tweak.
ED posted Q2 adjusted EPS of $0.83 vs $0.74 and reaffirmed FY26 adjusted EPS guidance of $6.00-$6.20.
Limited directional conviction; expect range-bound trading unless analysts revise estimates upward beyond the reaffirmation.
The beat and reaffirmation are real datapoints, yet the article explicitly says the near-term outlook is balanced and does not cite a surprise change in guidance.
EMR’s fiscal Q3 adjusted EPS rose to $1.71 and management raised FY26 outlook to ~5% net sales growth and ~$6.55 adjusted EPS.
Higher probability of upward estimate revisions and follow-through buying versus the other names.
The article includes multiple reinforcing datapoints: EPS beat, orders up, margin expansion, and explicit FY26 guidance increases plus cash flow and shareholder return expectations.
PH reported fiscal Q4 adjusted EPS of $9.27 vs $8.29 and said FY27 net sales and organic sales growth should be 5.5%-8.5%.
Potential for continued positive sentiment if the market treats the FY27 range as credible and margins/cash flow remain resilient.
The text provides clear beats and a forward growth range, but the excerpt cuts off before detailing any additional margin or cash-flow guidance beyond what is already stated.
Market effects
Reinforces demand and margin resilience narratives in medical technology (BDX), industrial automation and instrumentation (EMR), and aerospace/industrial components (PH), while utilities (ED) remain rate-base and valuation sensitive.
No specific regional macro linkage beyond general rate/valuation sensitivity for utilities.
Limited; these are company-specific earnings and guidance disclosures with no stated global policy or cross-border shock.
Counterpoint
The article’s Zacks Rank #3 (Hold) for BDX and ED suggests the market may already price much of the “dividend king” quality, limiting upside despite beats.
Key entities
- companyBecton, Dickinson and Company
Reported fiscal Q3 adjusted EPS beat and tightened FY26 adjusted EPS outlook; continuing-business growth and cash flow improved.
- companyConsolidated Edison
Reported Q2 adjusted EPS and revenue beat, reaffirmed FY26 adjusted EPS guidance, and highlighted a large 2026-2030 capex plan.
- companyEmerson Electric
Reported fiscal Q3 EPS and revenue beats, showed improving orders and margins, and raised FY26 outlook with free cash flow expectations.
- companyParker-Hannifin
Reported fiscal Q4 EPS and revenue beats, strong order growth, and provided FY27 sales growth and margin range guidance.
